세계의 암/종양 프로파일링 시장 보고서 : 암 유형별, 기술별, 수법별, 용도별, 지역별(2024-2032년)

The global cancer/tumor profiling market size reached US$ 11.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.6 Billion by 2032, exhibiting a growth rate (CAGR) of 8.6% during 2024-2032.

Cancer/tumor profiling, also known as biomarker testing, refers to a laboratory test or procedure used to identify specific proteins, genes or gene mutations (changes) and other biomarkers in a tumor tissue sample. It assists oncologists in determining if the pathways of a patient's tumor match up with the available targeted therapies. It also aids in routine diagnostics, therapeutic decision-making, and developing personalized treatment plans and therapies for individuals based on the severity of their ailment and genomic build-up. Cancer/tumor profiling also finds extensive applications in personalized medicine, research, the discovery of biomarkers, and the development of screening and diagnostic techniques.

Cancer/Tumor Profiling Market Trends:

Cancer/tumor profiling is widely used in oncology research and discovery of biomarkers during the process of drug design, discovery and development. As a result, the widespread prevalence of cancer across the globe represents the primary factor driving the market growth. Besides this, the growing focus on biomarkers for diagnosis and tumor profiling and the shifting preferences toward personalized medicine among the masses are augmenting the product demand. Additionally, there has been a significant rise in government funding and support for cancer research for the development of advanced techniques to reduce the time taken for the detection and identification of tumors. Along with this, the recent advancements in molecular biology techniques, such as next-generation sequencing (NGS), are accelerating the adoption of cancer/tumor profiling. Furthermore, the increasing investments by pharmaceutical and biotechnology companies in research and development (R&D) activities for the launch of novel therapies and new drug designing techniques are propelling the market growth. Other factors, including the rising number of clinical trials, growing adoption of immunoassay techniques, favorable reimbursement policies, improving healthcare infrastructure, and technological advancements, are also creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer/tumor profiling market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on cancer type, technology, technique and application.

Breakup by Cancer Type:

Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

Melanoma Cancer

Others

Breakup by Technology:

Next-Generation Sequencing (NGS)

Polymerase Chain Reaction (PCR)

Immunohistochemistry (IHC)

In-Situ Hybridization (ISH)

Microarray

Others

Breakup by Technique:

Genomics

Proteomics

Epigenetics

Metabolomics

Breakup by Application:

Personalized Medicine

Diagnostics

Biomarker Discovery

Prognostics

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Hologic Inc., HTG Molecular Diagnostics Inc., Illumina Inc., Laboratory Corporation of America Holdings, NeoGenomics Laboratories, Qiagen N.V., Siemens AG and Sysmex Corporation.

Key Questions Answered in This Report

• 1. What was the size of the global cancer/tumor profiling market in 2023?
• 2. What is the expected growth rate of the global cancer/tumor profiling market during 2024-2032?
• 3. What has been the impact of COVID-19 on the global cancer/tumor profiling market?
• 4. What are the key factors driving the global cancer/tumor profiling market?
• 5. What is the breakup of the global cancer/tumor profiling market based on the cancer type?
• 6. What is the breakup of the global cancer/tumor profiling market based on the technique?
• 7. What are the key regions in the global cancer/tumor profiling market?
• 8. Who are the key players/companies in the global cancer/tumor profiling market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Cancer/Tumor Profiling Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Cancer Type

• 6.1 Breast Cancer
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Lung Cancer
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Colorectal Cancer
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Prostate Cancer
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Melanoma Cancer
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Others
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast

7 Market Breakup by Technology

• 7.1 Next-Generation Sequencing (NGS)
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Polymerase Chain Reaction (PCR)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Immunohistochemistry (IHC)
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 In-Situ Hybridization (ISH)
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Microarray
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Technique

• 8.1 Genomics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Proteomics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Epigenetics
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Metabolomics
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Application

• 9.1 Personalized Medicine
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Diagnostics
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Biomarker Discovery
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Prognostics
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Others
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Becton Dickinson and Company
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Caris Life Sciences
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 Exact Sciences Corporation
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 F. Hoffmann-La Roche Ltd
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
  • 15.3.6 Hologic Inc.
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
    • 15.3.6.4 SWOT Analysis
  • 15.3.7 HTG Molecular Diagnostics Inc.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
  • 15.3.8 Illumina Inc.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Laboratory Corporation of America Holdings
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 NeoGenomics Laboratories
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
  • 15.3.11 Qiagen N.V.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis
  • 15.3.12 Siemens AG
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis
  • 15.3.13 Sysmex Corporation
    • 15.3.13.1 Company Overview
    • 15.3.13.2 Product Portfolio
    • 15.3.13.3 Financials
    • 15.3.13.4 SWOT Analysis